Advertisement

PentaVision

Ophthalmology Management

2025 News Archive

2025
2024
2023
2022

Thursday, April 17, 2025

FDA Reviews Eylea HD for RVO

The agency has initiated priority review of the anti-VEGF agent as a treatment for macular edema secondary to retinal vein occlusion.

Tuesday, April 8, 2025

Opus Genetics Reports Early LCA5 Trial Data

Preliminary results in a pediatric patient who underwent gene therapy to treat a form of Leber congenital amaurosis show improved vision and no safety issues.

Wednesday, March 26, 2025

Investigational Drug for Sjogren's Disease Granted Fast Track Designation From FDA

Maker Johnson & Johnson says nipocalimab, the first and only investigational treatment to be granted FDA Breakthrough Therapy Designation for the treatment of adults with mild to moderate Sjogren's, now has Fast Track designation as well. Currently, there are no FDA-approved advanced treatments for Sjogren’s disease.

Monday, March 24, 2025

Alcon Agrees to Acquire Lensar

The acquisition includes Ally Robotic Cataract Laser Treatment System, Lensar's proprietary Streamline software technology and Lensar legacy laser system, building Alcon’s femtosecond laser-assisted cataract surgery (FLACS) offering.

Thursday, March 20, 2025

Kalaris Closes Merger with AlloVir

Additionally, the company is currently enrolling nAMD patients in a phase 1 trial for its novel, differentiated anti-VEGF agent, TH103, for the treatment of neovascular and exudative diseases of the retina. Post-merger cash of approximately $100 million is expected to fund operations into the fourth quarter of 2026.

Tuesday, March 4, 2025

Outlook Therapeutics Resubmits BLA to FDA for ONS-5010 Ophthalmic Bevacizumab

The company said it believes that the complete data set for NORSE EIGHT and the additional CMC information in the BLA resubmission, combined with the data from the other NORSE clinical trials, provides the required evidence to support approval of the ONS-5010 BLA in the United States.

Tuesday, March 4, 2025

Digital Screen Time Increases Risk for Myopia

Each additional hour of daily screen time was associated with a 21% increase in the odds of developing myopia, according to a new analysis.

By Sarah Fackler

Tuesday, March 4, 2025

Altris AI Launches Advanced Optic Disc Analysis for Glaucoma

The AI-powered Advanced Optic Disc Analysis module evaluates optic disc parameters using optical coherence tomography, providing personalized assessments by accounting for individual disc sizes and angle of rim absence.

Tuesday, March 4, 2025

Opthea Publishes Phase 2b Wet AMD Data

The paper reports pre-specified and post-hoc analyses of angiographic predictors of response to sozinibercept combination therapy with ranibizumab in treatment-naïve patients with wet AMD. 

Thursday, February 27, 2025

Opthea Completes Drug Product Process Performance Qualification Campaign

The campaign consisted of the successful production of 3 consecutive commercial-scale drug product batches required to further validate Opthea’s manufacturing process in preparation for a potential biologics license application filing and commercialization of sozinibercept in wet AMD.

Tuesday, February 18, 2025

Opus Genetics Announces Update on OPGx-LCA5 Clinical Program

First patient dosed in the pediatric cohort of the phase 1/2 trial of OPGx-LCA5, with initial data anticipated by Q3 2025. Twelve-month data on the adult cohort to be released in the second quarter of the year.

Tuesday, February 18, 2025

Prevent Blindness Declares Second Annual Retinopathy of Prematurity Awareness Week

The initiative, taking place Feb. 24 to March 2, supports the comprehensive “Prevent Blindness ROP Education and Support Program,” designed to provide education and support for families of children with ROP, promote the role of early intervention programs for these children and explain how allied healthcare professionals assist in continuity of care.

Tuesday, February 18, 2025

Opthea Completes COAST Final Week 52 Patient Visit for Wet AMD

Opthea Limited completed the final week 52 patient visit in COAST, the first of two Phase 3 pivotal trials investigating the superiority and safety of sozinibercept in combination with aflibercept (COAST) or ranibizumab (ShORe), compared to standard of care alone for the treatment of wet AMD.

Tuesday, February 11, 2025

Virtual Vision Health Unveils Visual Acuity Testing for VR Device

Virtual Vision Health launched Visual Acuity testing on the Virtual Eye VR platform. The company said this addition is part of its commitment to expanding access to advanced eye care and equipping providers with a comprehensive, portable, and cloud-based diagnostic solution. 

Thursday, February 6, 2025

EyePoint Reports Positive Results From VERONA Trial for DME

Both Duravyu doses met the primary endpoint of extended time to first supplemental injection vs the aflibercept control, with the 2.7 mg dose delaying the need for additional treatment in 73% of patients. 

 

Tuesday, February 4, 2025

FDA Approves Genentech’s Susvimo for the Treatment of DME

Genentech’s Susvimo (ranibizumab injection) 100 mg/mL is the first continuous-delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME), the company said.

Monday, February 3, 2025

New Test Detects Parent-of-Origin in Retinoblastoma

Origin matters for this hereditary ocular cancer because researchers found that male and female copies of the mutation are associated with different disease trajectories, and so would likely influence physicians' treatment recommendations.

Thursday, January 30, 2025

Ocular Therapeutix Shares SOL-R Enrollment Progress, Next Steps for Axpaxli in NPDR

Ocular Therapeutix outlined the clinical progress across its registrational program for Axpaxli in wet age-related macular degeneration (wet AMD), plans to advance Axpaxli in non-proliferative diabetic retinopathy (NPDR), and the company’s strategic outlook for 2025 in its presentation at the 43rd Annual J.P. Morgan Healthcare Conference (JPM 2025).

Tuesday, January 28, 2025

Prevent Blindness Receives Largest Donation in Organization's 117-year History

Prevent Blindness received a $9.7 million donation from the Estate of Pamela Behrens, a long-time Florida resident and previous donor. The largest in Prevent Blindness's history, the donation will help support its mission to prevent blindness and preserve sight across the United States and its commitment to be a partner to organizations working to address eye health around the world.

Wednesday, January 22, 2025

MeiraGTx Receives Rare Pediatric Disease Designation from US FDA

The designation is for the company's AAV8-RK-RetGC program for the treatment of patients with Leber congenital amaurosis due to GUCY2D mutations (LCA1). It makes the fourth Rare Pediatric Disease Designation MeiraGTx has received for inherited retinal diseases.

Monday, January 13, 2025

Bausch + Lomb Acquires Whitecap Biosciences

With innovative therapies addressing glaucoma and geographic atrophy currently in development, the acquisition of Whitecap Biosciences strengthens B + L’s expanding clinical-stage pipeline. 

Thursday, January 2, 2025

Valo Health Suspends Development of Diabetic Retinopathy Drug

While the Phase 2 SPEC­TRA study did not meet its pri­ma­ry or sec­ondary end­points based on the analy­sis in the pre­de­fined pri­ma­ry pop­u­la­tion, cer­tain dos­es test­ed in the study showed poten­tial evi­dence of pre­vent­ing dis­ease pro­gres­sion.